11-chloro-3-hydroxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indole | 1262681-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 11-chloro-3-hydroxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indole
• 英文别名: 11-Chloro-8-Methyl-7h-Benzo[e]pyrido[4,3-B]indol-3-Ol；16-chloro-13-methyl-11,15-diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),2(7),3,5,8,12(17),13,15-octaen-5-ol
• CAS: 1262681-43-5
• 化学式: C₁₆H₁₁ClN₂O
• 分子量: 282.729
• InChiKey: WGZZCINOMPRGRY-UHFFFAOYSA-N

物化性质

• 沸点：
  595.6±45.0 °C(Predicted)
• 密度：
  1.488±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  11-chloro-3-hydroxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indole 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 72.0h， 生成 11-methoxy-3-[2-(N,N-dimethylamino)ethoxy]-8-methyl-7H-benzo[e]pyrido[4,3-b]indole
  参考文献：
  名称：

  [EN] AMINO-SUBSTITUTED-ALKYLOXY-BENZO[E]PYRIDO[4,3-B]INDOLE DERIVATIVES AS NEW POTENT KINASE INHIBITORS
  [FR] DÉRIVÉS D'ALKYLOXY-BENZO[E]PYRIDO[4,3-B]INDOLE SUBSTITUÉS PAR UN AMINO À TITRE DE NOUVEAUX PUISSANTS INHIBITEURS DE KINASES

  摘要：

  本发明涉及一种新的苯并[e]吡啶基吲哚类化合物，即氨基取代烷氧基苯并[e]吡啶[4,3-b]吲哚衍生物，具有特定的激酶抑制谱和作为治疗剂的用途，特别是作为抗肿瘤剂。

  公开号：

  WO2012163934A1

文献信息

• AMINO-SUBSTITUTED-ALKYLOXY-BENZO[E]PYRIDO[4,3-B]INDOLE DERIVATIVES AS NEW POTENT KINASE INHIBITORS
  申请人：INSTITUT CURIE

  公开号：US20140073637A1

  公开（公告）日：2014-03-13

  The present invention relates to a new class of benzo[e]pyrido-indole, the amino-substituted-alkyloxy-benzo[e]pyrido[4,3-b]indole derivatives, having a particular kinase inhibition profile and useful as a therapeutic agent, in particular an anti-tumoral agent.

  本发明涉及一种新的苯并[e]吡啶吲哚类化合物，即氨基取代烷氧基苯并[e]吡啶[4,3-b]吲哚衍生物，具有特定的激酶抑制谱和作为治疗剂的用途，特别是作为抗肿瘤剂。
• Condensed pyridine derivatives useful as potent inhibitors of the protein kinase CK2
  申请人：Commissariat à l'Énergie Atomique et aux Énergies Alternatives

  公开号：EP2280011A1

  公开（公告）日：2011-02-02

  The invention relates to the use of specific compounds of formula (I) and their pharmaceutically-acceptable salts: as a new family of protein kinase CK2 inhibitors; the invention also relates to the use of compounds of formula (I) for the preparation of pharmaceutical compositions for the prevention and/or treatment of disorders and/or diseases chosen amongst cancers; autoimmune and inflammatory diseases; infectious diseases; diabetes angiogenesis related disorders; retinopathies and cardiac hypertrophy.

  本发明涉及式 (I) 特定化合物及其药学上可接受的盐类的用途： 本发明还涉及使用式（I）化合物制备药物组合物，用于预防和/或治疗癌症、自身免疫性和炎症性疾病、传染性疾病、糖尿病血管生成相关疾病、视网膜病变和心肌肥大等疾病。
• Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US11364219B2

  公开（公告）日：2022-06-21

  The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.

  本发明涉及微生物组失调的治疗。这些失调可能会导致多种慢性疾病的发生。因此，对能诱导宿主-微生物群相互作用发生有益变化的新生物后化合物进行表征可能是非常可取的。本发明者的研究表明，Nlrp6 在使用 Csnk2 抑制剂治疗的情况下，会周期性地协调肠道微生物群多样性对上皮可塑性的适应。因此，本发明涉及一种 Csnk2 抑制剂，用于治疗主要与昼夜节律紊乱有关的微生物组失调。所述抑制剂可选择化学合成或天然选择性 Csnk2 抑制剂，如黄酮类。
• CONDENSED PYRIDINE DERIVATIVES USEFUL AS POTENT INHIBITORS OF THE PROTEIN KINASE CK2
  申请人：Cochet Claude

  公开号：US20120178759A1

  公开（公告）日：2012-07-12

  The invention relates to the use of specific compounds of formula (I) and their pharmaceutically-acceptable salts: (Formula 1) (I) as a new family of protein kinase CK2 inhibitors; the invention also relates to the use of compounds of formula (I) for the preparation of pharmaceutical compositions for the prevention and/or treatment of disorders and/or diseases chosen Camongst cancers; autoimmune and inflammatory diseases; infectious diseases; diabetes angiogenesis related disorders; retinopathies and cardiac hypertrophy.
• Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
  申请人：INSERM (Institut National de la Sante et de la Recherche Medicale)

  公开号：US20170051062A1

  公开（公告）日：2017-02-23

  The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.